Skip to main content
Ulka Vaishampayan, MD, Oncology, Ann Arbor, MI, DMC Detroit Receiving Hospital & University Health Center

UlkaNitinVaishampayanMD

Oncology • Ann Arbor, MI

Genitourinary Oncology

Director of Phase I at Rogel Cancer Center Professor of medicine/oncology University of Michigan Ann Arbor MI

Join to view full profile

Dr. Vaishampayan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Vaishampayan's full profile

Already have an account?

  • Office

    7217 Rogel cancer center
    1500 E Medical center dr
    Ann Arbor, MI 48109
    Phone+1 734-647-8903
    Fax+1 734-232-9357
  • Is this information wrong?

Summary

  • Dr. Ulka Vaishampayan is an oncologist practicing at University of Michigan Ann Arbor MI. She received her medical degree from B.J. Medical College - University of Pune and has been in practice 24 years. She specializes in medical oncology and is experienced in urologic and general medical oncology. Her research focus is clinical trials and drug development and novel biomarkers in cancer.

Education & Training

  • Detroit Medical Center/Wayne State University
    Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1997 - 2000
  • Wayne State University School of Medicine
    Wayne State University School of MedicineResidency, Internal Medicine, 1994 - 1997
  • B.J. Medical College - University of Pune
    B.J. Medical College - University of PuneClass of 1993

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 1997 - 2026
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Is a clinical biomarker predictive of outcomes with immune checkpoint inhibitor (ICI) therapy in a phase I patient population. 
    2019 ASCO Annual Meeting - 6/1/2019
  • A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Join now to see all

Press Mentions

  • Rare Disease Day with Thomas Abrams, MD; Maria Badillo, MSN, RN, OCN®, CCRP; And Ulka Vaishampayan, MD
    Rare Disease Day with Thomas Abrams, MD; Maria Badillo, MSN, RN, OCN®, CCRP; And Ulka Vaishampayan, MDMarch 20th, 2023
  • Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage Cancers
    Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage CancersMay 26th, 2022
  • ASCO GU 2021: Phase IIb Trial of Oral ModraDoc006/ritonavir as a Tolerable and Effective Option in Comparison with Intravenous Docetaxel in mCRPC
    ASCO GU 2021: Phase IIb Trial of Oral ModraDoc006/ritonavir as a Tolerable and Effective Option in Comparison with Intravenous Docetaxel in mCRPCFebruary 12th, 2021
  • Join now to see all

Professional Memberships

Hospital Affiliations

Dr. Ulka Vaishampayan, Dr. Ulka Vaishampayan, MD, Dr. U Vaishampayan, Dr. Ulka Nitin Vaishampayan